Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Alexion Pharmaceuticals, Inc.32 enrolled

Overview

The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP.

Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs, including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure. There are no approved disease-modifying treatments for patients with this disease. There is also limited data available on the natural course of this disease over time, particularly in patients with the juvenile-onset form.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hypophosphatasia (HPP)

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented informed consent unless patient is deceased * Patients with Juvenile-onset HPP, defined as documented onset of first signs/symptoms at ≥ 6 months to ˂18 years * Documented diagnosis of HPP as indicated by skeletal manifestations and low alkaline phosphatase or genotyping Exclusion Criteria: * Received treatment with asfotase alfa in the ENB-006-09 study and/or currently enrolled in the ENB-008-10 study * Received other treatment and/or intervention to treat HPP up to 15 years old * Other clinically significant disease

Locations (19)

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Indianapolis, Indiana, United States

Unnamed facility

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Radiographic Global Impression of Change - RGI-C

The RGI-C scale is a 7-point ordinal scale that is used to evaluate musculoskeletal characteristics of HPP (eg, metaphyseal fraying, demineralization of distal metaphyses). The scores range from -3 (severe worsening) to +3 (complete or near-complete healing).

Time frame: Between Baseline (earliest available, complete, and readable x-ray set) and all available, readable post-Baseline x-ray sets during the period of patients' aged 5 to 15 years, inclusive.

Secondary Outcomes

Change in Height Z-score From Baseline to Last Assessment

Height measurements were assigned to Z-scores which were calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z-scores indicate a better outcome.

Time frame: Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while post baselines are time points after Baseline during the defined age period.

Change in Weight Z-score From Baseline to Last Assessment

Weight measurements were assigned a Z-score which was calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z-scores indicate a better outcome.

Time frame: Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while Post baselines are time points after Baseline during the defined age period.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.